Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Under normal circumstances, the study of health problems after COVID vaccinations posted online on Feb. 25 might not have generated much controversy.Its principal authors were well-respected ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

The Düsseldorf Regional Court has ordered Pfizer and its German partner BioNTech to pay damages for the use of Moderna’s ...

Moderna's COVID sales have been declining, and the company has been trimming costs. But it doesn't have a huge growth ...

The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...

The next-generation cost needs to be added to the long-term effects on vaccinees. Yet, Dr. Hatfill writes, the American College of Obstetrics and Gynecology (ACOG) has continued to promote the mass ...